Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Geron stock price, quote, forecast and news

GERN
US3741631036
902213

Price

4.54
Today +/-
+0.05
Today %
+1.33 %
P

Geron stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Geron stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Geron stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Geron stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Geron's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Geron Stock Price History

DateGeron Price
8/23/20244.54 undefined
8/22/20244.48 undefined
8/21/20244.54 undefined
8/20/20244.62 undefined
8/19/20244.46 undefined
8/16/20244.50 undefined
8/15/20244.46 undefined
8/14/20244.44 undefined
8/13/20244.57 undefined
8/12/20244.73 undefined
8/9/20244.70 undefined
8/8/20244.60 undefined
8/7/20244.56 undefined
8/6/20244.60 undefined
8/5/20244.51 undefined
8/2/20244.57 undefined
8/1/20244.78 undefined
7/31/20244.74 undefined
7/30/20244.69 undefined
7/29/20244.69 undefined
7/26/20244.66 undefined

Geron Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Geron, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Geron from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Geron’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Geron. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Geron’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Geron’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Geron’s growth potential.

Geron Revenue, EBIT and net profit per share

DateGeron RevenueGeron EBITGeron Net Income
2029e1.34 B undefined0 undefined372.07 M undefined
2028e1.08 B undefined523.35 M undefined278.3 M undefined
2027e725.94 M undefined265.6 M undefined104.85 M undefined
2026e512.62 M undefined87.8 M undefined69.57 M undefined
2025e257.56 M undefined-119.25 M undefined-108.09 M undefined
2024e53.07 M undefined-229.81 M undefined-212.01 M undefined
2023237,000 undefined-193.94 M undefined-184.13 M undefined
2022600,000 undefined-138.55 M undefined-141.9 M undefined
20211.39 M undefined-114 M undefined-116.11 M undefined
2020250,000 undefined-76.91 M undefined-75.62 M undefined
2019460,000 undefined-72.51 M undefined-68.55 M undefined
20181.07 M undefined-31.07 M undefined-27.02 M undefined
20171.07 M undefined-29.26 M undefined-27.92 M undefined
20166.16 M undefined-30.65 M undefined-29.54 M undefined
201536.37 M undefined750,000 undefined50,000 undefined
20141.15 M undefined-36.31 M undefined-35.67 M undefined
20131.28 M undefined-37.5 M undefined-38.38 M undefined
20122.71 M undefined-69.06 M undefined-68.88 M undefined
20112.44 M undefined-90.67 M undefined-96.85 M undefined
20103.56 M undefined-76.17 M undefined-111.38 M undefined
20091.73 M undefined-70.23 M undefined-70.37 M undefined
20082.8 M undefined-67.04 M undefined-62.02 M undefined
20077.62 M undefined-62.84 M undefined-45.78 M undefined
20063.28 M undefined-47.36 M undefined-31.37 M undefined
20056.16 M undefined-37.71 M undefined-33.69 M undefined
20041.05 M undefined-36.14 M undefined-79.56 M undefined

Geron Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
1991199219931994199519961997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e2027e2028e2029e
00000.010.010.010.010.010.0100000.0100.0100000000.040.0100000000.050.270.530.731.081.34
------40.00-14.29-16.6720.00-50.00-66.67--500.00-50.00133.33-71.43-50.00200.00-33.33--50.00-3,500.00-83.33-83.33-------415.3897.3937.0548.4124.91
---------------------------------------
000000000000000000000000000000000000000
0-1-6-10-8-12-11-12-20-26-35-35-30-36-37-47-62-67-70-76-90-69-37-360-30-29-31-72-76-114-138-193-229-119872655230
-----160.00-240.00-157.14-200.00-400.00-433.33-1,166.67-3,500.00-3,000.00-3,600.00-616.67-1,566.67-885.71-3,350.00-7,000.00-2,533.33-4,500.00-3,450.00-3,700.00-3,600.00--500.00-2,900.00-3,100.00---11,400.00---440.38-44.4016.4536.5548.61-
0-1-5-10-8-10-9-11-46-45-42-33-29-79-33-31-45-62-70-111-96-68-38-350-29-27-27-68-75-116-141-184-216-10571104278372
--400.00100.00-20.0025.00-10.0022.22318.18-2.17-6.67-21.43-12.12172.41-58.23-6.0645.1637.7812.9058.57-13.51-29.17-44.12-7.89---6.90-151.8510.2954.6721.5530.5017.39-51.39-167.6246.48167.3133.81
7.957.957.957.956.128.510.5511.4415.4920.8722.1224.6630.9744.8857.8866.0674.2178.1988.0897.6124.51126.94128.38153.54162.66159.05159.22176.51190.16271.46327.63380.78570.65000000
---------------------------------------
Details

Keystats

ⓘ

Revenue and Growth

The Geron Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Geron is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (k)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (M)NON-CURRENT ASSETS (M)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
13.915.624.321.624.539.332.579.147109.3120190.5213.3206162.8111.6186.6121.395.565.2151.4113.8114.894.7163.3139.3196.3183.7172.7333.7
000000000000000000000000000000
000000000000000000000000000000
000000000000000000000000000000
0.20.30.40.70.70.40.91.22.61.23.12.82.56.54.54.96.72.92.11.310.90.80.91.61.52.91.84.45.99
14.115.924.722.325.239.733.480.349.6110.5123.1193.3215.8212.5167.3116.5193.3124.297.666.5152.4114.7115.695.6164.9140.8199.2185.5177.1339.69
2.42.732.42.33.83.73.62.41.72.12.82.54.14.43.93.11.210.10.20.20.20.10.12.965.44.94.73
0000163.662.80.70.40.40.50.30.20.10.75634.432.10018.932.71414.219.22063.728.7043.3
300800600010030030030020020000000000000000000000
0000015.312.49.56.73.81.10.4000000000000000000
000000000000000000000000000000
0.30.30.20.20.20.30.30.20.20.43.42.111.42.92.71.110.40.20000011.24.85.44.7
33.83.82.618.623.379.514.39.96.57.15.63.75.6862.638.634.31.40.319.132.914.214.319.323.970.938.910.352.73
17.119.728.524.943.863112.994.659.5117130.2198.9219.5218.1175.3179.1231.9158.59966.8171.5147.6129.8109.9184.2164.7270.1224.4187.4392.42
00003.6000000.10.10.10.10.10.10.10.10.10.10.20.20.20.20.20.20.30.30.40.55
0.030.040.060.070.090.130.210.250.260.360.460.540.570.650.680.750.880.930.940.951.061.071.081.091.191.211.371.41.491.84
-17.6-25.8-36.5-46.1-57.5-104-149.8-191.9-225.8-255.7-336.1-367.7-399.1-444.9-506.9-577.3-688.7-785.5-854.4-892.8-928.4-928.4-957.9-985.8-1,011.5-1,080-1,155.6-1,271.7-1,413.6-1,597.77
00-1,000-700-1,400-900-300-200-600-700-900-900-20000-400-200-20000-100-200-100-200-200100100-200-200185
0000000000000000100100000000000000
13.714.323.621.132.826.263.961.529.7106.3122.1175.7174205.6168.4172.6192.7146.685.659.7130.8142.2122.4103.9177.7135.1211126.480.1247.95
0.50.50.80.71.21.31.51.31.61.32.51.923.92.72.23.533.41.410.20.20.511.26.96.710.26.16
0.611.611.22.71.331.73.32.83.85.25.73.43.78.810.410.75.85.86.57.66412.72438.845.655.02
01.3010.200.60.80.50.20.517.239.73.11.71.628.60.10.10.4350002.614.30000
000000000000000000000000000000
0.611.210.93.94.85.25.552.61.5000000000000000020.946.89
1.73.83.63.73.57.98.210.39.39.88.424.446.912.77.87.540.913.514.27.641.86.77.86.57.628.230.945.576.7108.07
1.61.71.61.38.129.54223.320.51.20.60000000000000002449.830.235.05
000000000000000000000000000000
00000001.110.80.71.20.10.50.10.40000000002.24.84.33.73.01
1.61.71.61.38.129.54224.421.521.31.20.10.50.10.40000000002.228.854.133.938.06
3.35.55.2511.637.450.234.730.811.89.725.64713.27.97.940.913.514.27.641.86.77.86.57.630.459.799.6110.6146.13
1719.828.826.144.463.6114.196.260.5118.1131.8201.3221218.8176.3180.5233.6160.199.867.3172.6148.9130.2110.4185.3165.5270.7226190.7394.08
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Geron provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Geron's financial health and stability.

Assets

Geron's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Geron must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Geron after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Geron's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (M)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES ()TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
1993199419951996199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-5-10-8-10-9-10-46-45-42-33-29-79-33-31-36-62-70-111-96-68-38-350-29-27-27-68-75-116-141-184
0000113444431112111000000000000
0000000000000000000000000000000
0010000-1-1-40-144946984-43402-101901056
000001302917325170-124287039131018-151716121115171728
0000000000000000000000000000000
0000000000000000000000000000000
-5-10-6-9-7-7-13-13-22-30-23-25-20-26-26-41-43-44-62-55-369-24-18-20-21-43-66-95-127-167
000-10-1-2-1-100-1-10-2-2-100000000000000
-1023-10-6-7-12-31316-55-181216165-83-48326021-770822-7727-1057162-180
-924-8-5-6-10-30416-55-161417197-81-47326121-770822-7727-1047262-179
0000000000000000000000000000000
000007202300000000000000000002324029
1512819620-2438087419448200511040069821192191442387332
161281952718677087419448200511040069821192191684887362
-------------------------------
0000000000000000000000000000000
0460-812-822-11-148-2863910-36-7411-295-929-21-83-53-3242113
-5.88-10.14-6.8-11.07-8.57-8.82-16.54-15.1-23.53-30.57-23.47-27.46-22.25-27.16-29.62-44.33-44.81-45.13-63-56.01-36.689.22-24.29-18.43-20.56-21.03-44.24-67.05-95.77-127.81-168.57
0000000000000000000000000000000

Geron stock margins

The Geron margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Geron. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Geron.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Geron's sales revenue. A higher gross margin percentage indicates that the Geron retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Geron's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Geron's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Geron's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Geron. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Geron's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Geron Margin History

Geron Gross marginGeron Profit marginGeron EBIT marginGeron Profit margin
2029e0 %0 %27.68 %
2028e0 %48.59 %25.84 %
2027e0 %36.59 %14.44 %
2026e0 %17.13 %13.57 %
2025e0 %-46.3 %-41.97 %
2024e0 %-433.06 %-399.51 %
20230 %-81,832.91 %-77,690.72 %
20220 %-23,091.67 %-23,650 %
20210 %-8,201.44 %-8,353.24 %
20200 %-30,764 %-30,248 %
20190 %-15,763.04 %-14,902.17 %
20180 %-2,903.74 %-2,525.23 %
20170 %-2,734.58 %-2,609.35 %
20160 %-497.56 %-479.55 %
20150 %2.06 %0.14 %
20140 %-3,157.39 %-3,101.74 %
20130 %-2,929.69 %-2,998.44 %
20120 %-2,548.34 %-2,541.7 %
20110 %-3,715.98 %-3,969.26 %
20100 %-2,139.61 %-3,128.65 %
20090 %-4,059.54 %-4,067.63 %
20080 %-2,394.29 %-2,215 %
20070 %-824.67 %-600.79 %
20060 %-1,443.9 %-956.4 %
20050 %-612.18 %-546.92 %
20040 %-3,441.9 %-7,577.14 %

Geron Stock Sales Revenue, EBIT, Earnings per Share

The Geron earnings per share therefore indicates how much revenue Geron has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Geron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Geron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Geron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Geron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Geron Revenue, EBIT and net profit per share

DateGeron Sales per ShareGeron EBIT per shareGeron Earnings per Share
2029e2.27 undefined0 undefined0.63 undefined
2028e1.82 undefined0 undefined0.47 undefined
2027e1.22 undefined0 undefined0.18 undefined
2026e0.86 undefined0 undefined0.12 undefined
2025e0.43 undefined0 undefined-0.18 undefined
2024e0.09 undefined0 undefined-0.36 undefined
20230 undefined-0.34 undefined-0.32 undefined
20220 undefined-0.36 undefined-0.37 undefined
20210 undefined-0.35 undefined-0.35 undefined
20200 undefined-0.28 undefined-0.28 undefined
20190 undefined-0.38 undefined-0.36 undefined
20180.01 undefined-0.18 undefined-0.15 undefined
20170.01 undefined-0.18 undefined-0.18 undefined
20160.04 undefined-0.19 undefined-0.19 undefined
20150.22 undefined0 undefined0 undefined
20140.01 undefined-0.24 undefined-0.23 undefined
20130.01 undefined-0.29 undefined-0.3 undefined
20120.02 undefined-0.54 undefined-0.54 undefined
20110.02 undefined-0.73 undefined-0.78 undefined
20100.04 undefined-0.78 undefined-1.14 undefined
20090.02 undefined-0.8 undefined-0.8 undefined
20080.04 undefined-0.86 undefined-0.79 undefined
20070.1 undefined-0.85 undefined-0.62 undefined
20060.05 undefined-0.72 undefined-0.47 undefined
20050.11 undefined-0.65 undefined-0.58 undefined
20040.02 undefined-0.81 undefined-1.77 undefined

Geron business model

Geron Corp is a biopharmaceutical company headquartered in Menlo Park, California, founded in 1990. The company's goal is to develop innovative products and therapies that have the potential to combat serious diseases. Geron Corp specializes in the research of embryonic stem cells. The company is a pioneer in researching technologies for the use of stem cells and has made significant breakthroughs in the field of regenerative medicine. By developing new stem cell therapies, Geron Corp aims to improve the lives of patients with serious conditions such as cancer, Parkinson's disease, and spinal cord injuries. Geron Corp operates various business segments, including oncology, regenerative medicine, and RNA-based therapies. In the field of oncology, the company focuses on developing therapies for the treatment of cancer, particularly solid tumors. One of the most important developments is the drug Imetelstat, which aims to extend the telomeres of cancer cells by inhibiting the activity of telomerase. Imetelstat is currently in various clinical trials and has the potential to revolutionize the treatment of leukemia and other types of cancer. Another important business segment of Geron Corp is regenerative medicine, particularly the research of therapies for repairing spinal cord injuries. The company has made significant breakthroughs in this area and has a promising pipeline of products aimed at repairing damaged nerve cells in the spinal cord and restoring patients' mobility. Geron Corp is also a leading company in the field of RNA-based therapies. RNA-based therapies aim to regulate gene activity to treat diseases. The company has developed various innovative technologies aimed at accelerating and enhancing the development of RNA-based therapies. In recent years, Geron Corp has brought a variety of products to the market, including drugs for the treatment of spinal cord injuries, leukemia, and other types of cancer. The company has also formed partnerships with other leading companies in the biopharmaceutical industry to advance the development and commercialization of products. Overall, Geron Corp has made a significant contribution to the research and development of new technologies and therapies with the potential to improve the lives of millions of people. The company has a promising pipeline of products and is committed to further solidifying its position as a leading company in the biopharmaceutical industry. Geron is one of the most popular companies on Eulerpool.com.

Geron SWOT Analysis

Strengths

Geron Corp has a strong track record in the field of stem cell research, which gives them a competitive advantage in the biotechnology industry.

The company's innovative technologies and therapies have the potential to revolutionize the treatment of various diseases.

Geron Corp has a robust intellectual property portfolio, providing them with a solid foundation for future growth and revenue generation.

Weaknesses

One of the main weaknesses of Geron Corp is its heavy reliance on the success of its research and development projects, which can be risky and uncertain.

The company has a limited product pipeline, which may impact its ability to generate sustainable revenue in the long term.

Geron Corp also faces regulatory challenges and strict government guidelines in relation to stem cell research, which can impede their progress and limit market opportunities.

Opportunities

The increasing demand for novel therapies and treatments in the healthcare industry presents a significant opportunity for Geron Corp to expand its market presence.

Collaboration with other biotechnology and pharmaceutical companies could enhance their research capabilities, accelerate product development, and create new revenue streams.

The growing aging population worldwide opens up potential markets for Geron Corp's regenerative medicine solutions, targeting age-related diseases.

Threats

Intense competition within the biotechnology sector poses a threat to Geron Corp's market position and potential market share.

The constantly evolving regulatory landscape around stem cell research and related therapies may hinder the company's ability to bring their products to market.

Uncertainty surrounding intellectual property rights and potential legal disputes can negatively impact Geron Corp's business operations and profitability.

Geron Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Geron historical P/E ratio, EBIT, and P/S ratio.

Geron shares outstanding

The number of shares was Geron in 2023 — This indicates how many shares 570.645 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Geron earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Geron's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Geron’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Geron's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Unfortunately, there are currently no price targets and forecasts available for Geron.

Geron latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/2024-0.11 -0.1  (6.02 %)2024 Q2
3/31/2024-0.1 -0.09  (9.73 %)2024 Q1
12/31/2023-0.11 -0.09  (15.97 %)2023 Q4
9/30/2023-0.1 -0.08  (20.24 %)2023 Q3
6/30/2023-0.09 -0.09  (-5.88 %)2023 Q2
3/31/2023-0.1 -0.07  (31.37 %)2023 Q1
12/31/2022-0.13 -0.1  (21.57 %)2022 Q4
9/30/2022-0.1 -0.1  (-5.04 %)2022 Q3
6/30/2022-0.1 -0.07  (27.01 %)2022 Q2
3/31/2022-0.11 -0.09  (15.17 %)2022 Q1
1
2
3
4
5
...
9

Eulerpool ESG Scorecard© for the Geron stock

Eulerpool World ESG Rating (EESG©)

72/ 100

🌱 Environment

76

👫 Social

88

🏛️ Governance

53

Environment

Scope 1 - Direct Emissions
—
Scope 2 - Indirect emissions from purchased energy
—
Scope 3 - Indirect emissions within the value chain
—
Total CO₂ emissions
—
CO₂ reduction strategy
✅
Coal energy
❌
Nuclear power
❌
Animal experiments
✅
Fur & Leather
—
Pesticides
—
Palm Oil
—
Tobacco
❌
Genetically modified organisms
❌
Climate concept
—
Sustainable forestry
—
Recycling regulations
❌
Environmentally friendly packaging
❌
Hazardous substances
❌
Fuel consumption and efficiency
❌
Water consumption and efficiency
❌

Social

Percentage of female employees—
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content❌
Alcohol❌
Weapons—
Firearms
❌
Gambling❌
Military contracts❌
Human rights concept❌
Privacy concept—
Occupational health and safety✅
Catholic✅

Governance (Corporate Governance)

Environmental reporting❌
Stakeholder Engagement❌
Call Back Policies❌
Antitrust law❌

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Geron list of shareholders

%
Name
Stocks
Change
Date
7.79 % RA Capital Management, LP46,202,425012/31/2023
6.41 % BlackRock Institutional Trust Company, N.A.38,042,6214,941,60712/31/2023
4.99 % Deep Track Capital LP29,583,4493,883,44912/31/2023
4.80 % The Vanguard Group, Inc.28,475,2121,914,32812/31/2023
4.32 % State Street Global Advisors (US)25,625,606254,22112/31/2023
4.07 % Vivo Capital, LLC24,143,6817,619,04712/31/2023
3.94 % TCG Crossover Management, LLC23,375,839012/31/2023
3.84 % New Enterprise Associates (NEA)22,776,409012/31/2023
2.48 % Millennium Management LLC14,730,986-1,342,12012/31/2023
1.85 % Geode Capital Management, L.L.C.10,943,649930,74712/31/2023
1
2
3
4
5
...
10

Geron Executives and Management Board

Dr. John Scarlett72
Geron Chairman of the Board, President, Chief Executive Officer (since 2011)
Compensation 3 M
Dr. Andrew Grethlein58
Geron Executive Vice President, Chief Operating Officer
Compensation 1.37 M
Ms. Melissa Kelly Behrs59
Geron Executive Vice President - Business Operations, and Chief Alliance Officer
Compensation 1.15 M
Mr. Anil Kapur53
Geron Executive Vice President, Corporate Strategy and Chief Commercial Officer
Compensation 1.05 M
Mr. Stephen Rosenfield73
Geron Executive Vice President, Corporate Secretary, Chief Legal Officer
Compensation 1.01 M
1
2
3

Most common questions regarding Geron

What values and corporate philosophy does Geron represent?

Geron Corp is a biotechnology company that focuses on the development of innovative therapies to treat cancer and other diseases. The company prides itself on its commitment to scientific excellence, patient-centric approach, and dedicated team of skilled professionals. Geron Corp upholds a corporate philosophy rooted in transparency, integrity, and social responsibility. By prioritizing rigorous research and development, Geron Corp aims to deliver breakthrough treatments that can significantly improve patients' lives. With a strong emphasis on innovation and collaboration, the company continually strives to push the boundaries of medical science and make a positive impact in the healthcare industry.

In which countries and regions is Geron primarily present?

Geron Corp is primarily present in the United States.

What significant milestones has the company Geron achieved?

Geron Corp has achieved several significant milestones. One of their key achievements includes the development of imetelstat, a telomerase inhibitor that shows promising potential in treating hematologic myeloid malignancies. Additionally, Geron Corp successfully completed the IMerge Phase 2 clinical trial, which demonstrated positive results in myelodysplastic syndromes (MDS) patients. The company also received Fast Track designation from the U.S. FDA for imetelstat in MDS, further highlighting its progress in advancing this innovative therapy. Geron Corp's ability to develop groundbreaking treatments and achieve important clinical trial milestones has positioned them as a leading player in the biopharmaceutical industry.

What is the history and background of the company Geron?

Geron Corp, founded in 1990, is a biopharmaceutical company based in California, USA. The company focuses on the development of innovative therapeutic products for the treatment of cancer and other age-related diseases. Geron Corp has made significant advancements in the field of telomerase inhibition and embryonic stem cell research. Over the years, Geron Corp has collaborated with various renowned institutions and companies to advance its research and development efforts. With its commitment to pioneering medical breakthroughs, Geron Corp continues to strive towards improving patients' lives through the discovery and development of novel therapies.

Who are the main competitors of Geron in the market?

The main competitors of Geron Corp in the market include other pharmaceutical companies specializing in the field of oncology and stem cell research. Some prominent competitors of Geron Corp are Celgene Corporation, Biogen Inc., Johnson & Johnson, Novartis AG, and Amgen Inc. These companies also focus on developing innovative treatments and therapies for various types of cancer and other diseases.

In which industries is Geron primarily active?

Geron Corp is primarily active in the biotechnology industry.

What is the business model of Geron?

The business model of Geron Corp revolves around the development of innovative biopharmaceutical products. Geron focuses primarily on the research and development of telomerase inhibitors, which have the potential to treat various types of cancer. By targeting telomerase, an enzyme that plays a key role in cell immortality, Geron aims to disrupt the growth of cancer cells. The company works towards advancing its drug candidates through clinical trials and collaborations with healthcare organizations. Geron's commitment to scientific excellence and its dedication to improving patient outcomes drive its business model and guide its efforts in the field of oncology.

What is the P/E ratio of Geron 2024?

The Geron P/E ratio is -12.22.

What is the P/S ratio of Geron 2024?

The Geron P/S ratio is 48.82.

What is the AlleAktien quality score of Geron?

The AlleAktien quality score for Geron is 4/10.

What is the revenue of Geron 2024?

The expected Geron revenue is 53.07 M USD.

How high is the profit of Geron 2024?

The expected Geron profit is -212.01 M USD.

What is the business model of Geron

Geron Corp is an American biotechnology company that focuses on the development of therapeutics for diseases such as cancer and neurodegenerative disorders. The company was founded in 1990 and has been listed on NASDAQ since 1996. The company operates in two main divisions: oncology and regenerative medicine. Within each division, Geron Corp offers several products targeting different diseases and therapeutic approaches. Geron Corp's oncology division focuses on the development of therapeutics for cancer treatment. The company has developed a drug called Imetelstat, which has been tested in clinical trials for the treatment of various forms of cancer, including myelodysplastic syndrome (MDS), leukemia, and non-Hodgkin lymphoma. Imetelstat targets the inhibition of telomerase, an enzyme that is upregulated in many cancers and supports tumor cell growth. The company is also working on the development of immunotherapies and other novel treatment approaches for cancer. Geron Corp's regenerative medicine division focuses on the research and development of therapeutics for tissue and organ restoration and regeneration. The company has developed a technology called GRNOPC1, which targets neural precursor cells that can be used to repair damaged nerve tissue. The company is also working on the development of stem cell therapies for the treatment of heart and lung diseases, as well as other conditions that require tissue or organ regeneration. Geron Corp has established several partnerships with other companies in the biotechnology sector and pharmaceutical industry to support the development and commercialization of its products. The company also collaborates closely with academic research institutions and regulatory authorities to further develop and test its technologies and products. As a biotechnology company, Geron Corp heavily relies on the success of clinical trials and government approvals of its therapeutics. Investments in research and development of new products are significant, and the company's success depends on regularly bringing new therapeutics to market and successfully marketing its products. In summary, the business model of Geron Corp is based on the development and commercialization of novel therapeutics for the treatment of cancer and neurodegenerative diseases, as well as tissue and organ regeneration. The company operates in two main divisions, offers multiple products, and collaborates with various partners to support the development and commercialization of its products. As a biotechnology company, Geron Corp heavily depends on the success of its clinical trials and the approval of new products, and the company invests heavily in research and development to drive its growth.

What is the Geron dividend?

Geron pays a dividend of 0 USD distributed over payouts per year.

How often does Geron pay dividends?

The dividend cannot currently be calculated for Geron or the company does not pay out a dividend.

What is the Geron ISIN?

The ISIN of Geron is US3741631036.

What is the Geron WKN?

The WKN of Geron is 902213.

What is the Geron ticker?

The ticker of Geron is GERN.

How much dividend does Geron pay?

Over the past 12 months, Geron paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Geron is expected to pay a dividend of 0 USD.

What is the dividend yield of Geron?

The current dividend yield of Geron is .

When does Geron pay dividends?

Geron pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Geron?

Geron paid dividends every year for the past 0 years.

What is the dividend of Geron?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Geron located?

Geron is assigned to the 'Health' sector.

Wann musste ich die Aktien von Geron kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Geron from 8/24/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 8/24/2024.

When did Geron pay the last dividend?

The last dividend was paid out on 8/24/2024.

What was the dividend of Geron in the year 2023?

In the year 2023, Geron distributed 0 USD as dividends.

In which currency does Geron pay out the dividend?

The dividends of Geron are distributed in USD.

All fundamentals about Geron

Our stock analysis for Geron Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Geron Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.